Ripretinib manufacturers
- Ripretinib
-
- $0.00 / 1g
-
2025-01-07
- CAS:1442472-39-0
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Ripretinib.
-
- $0.00 / 1g
-
2025-01-07
- CAS:1442472-39-0
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Ripretinib
-
- $419.00 / 1mg
-
2024-11-19
- CAS:1442472-39-0
- Min. Order:
- Purity: 99.72%
- Supply Ability: 10g
Related articles - Synthesis of Ripretinib
- Ripretinib was synthesized by construction of a 1,6-naphtholide involving the junction of an α-aryl ester and appropriately fu....
- Jan 2，2024
|
| | Ripretinib Basic information |
| Product Name: | Ripretinib | | Synonyms: | KIT/PDGFR inhibitor(DCC2618);Ripretinib;DCC-2618; DCC 2618; DCC2618; RIPRETINIB;;DCC-2618;KIT/PDGFR INHIBITOR;KIT/PDGFR inhibitor;N-[4-Bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-phenylurea;Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-phenyl-;1-(4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl)-3-phenylurea | | CAS: | 1442472-39-0 | | MF: | C24H21BrFN5O2 | | MW: | 510.36 | | EINECS: | | | Product Categories: | API | | Mol File: | 1442472-39-0.mol |  |
| | Ripretinib Chemical Properties |
| Boiling point | 568.6±50.0 °C(Predicted) | | density | 1.544±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:25.0(Max Conc. mg/mL);49.0(Max Conc. mM) | | form | A solid | | pka | 12.15±0.70(Predicted) | | color | White to light yellow |
| | Ripretinib Usage And Synthesis |
| Uses | Ripretinib is used in the treatment of gastrointestinal stromal tumors (GISTs). | | Brand name | Qinlock | | General Description | Class: receptor tyrosine kinase;
Treatment: GIST;
Other name: DCC-2618;
Elimination half-life = 15 h;
Protein binding = 98.8% | | Biological Activity | Ripretinib is a highly effective inhibitor of both wild-type KIT and PDGFRA, with IC50 values around 3 nM. It also targets a wide range of KIT and PDGFRA mutants in GIST. Additionally, it inhibits various tumor-driving kinases such as PDGFRβ, TIE2, VEGFR2, and BRAF. | | target | Primary targets: PDGFRA, KIT |
| | Ripretinib Preparation Products And Raw materials |
|